Stockreport

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures Praxis plans to initiate an efficacy study in focal onset epile [Read more]